|
|
| Year : 2011 | Volume
: 3
| Issue : 2 | Page : 143-150 |
|
| Tuberculosis: Current situation, challenges and overview of its control programs in India |
|
|
Gursimrat K Sandhu
Faculty of Medicine, Lund University, Lund, Sweden
Click here for correspondence address and email
| Date of Web Publication | 27-May-2011 |
|
|
 |
|
 Abstract | | |
Tuberculosis (TB) is one of the most ancient diseases of mankind, with molecular evidence going back to over 17,000 years. In spite of newer modalities for diagnosis and treatment of TB, unfortunately, people are still suffering, and worldwide it is among the top 10 killer infectious diseases, second only to HIV. According to World Health Organization (WHO), TB is a worldwide pandemic. It is a leading cause of death among HIV-infected people. In India, historically speaking, fight against TB can be broadly classified into three periods: early period, before the discoveries of x-ray and chemotherapy; post-independence period, during which nationwide TB control programs were initiated and implemented; and the current period, during which the ongoing WHO-assisted TB control program is in place. Today, India's DOTS (directly observed treatment-short course) program is the fastest-expanding and the largest program in the world in terms of patients initiated on treatment; and the second largest, in terms of population coverage. Major challenges to control TB in India include poor primary health-care infrastructure in rural areas of many states; unregulated private health care leading to widespread irrational use of first-line and second-line anti-TB drugs; spreading HIV infection; lack of political will; and, above all, corrupt administration. Multidrug-resistant TB (MDR-TB) is another emerging threat to TB eradication and is a result of deficient or deteriorating TB control program. WHO with its "STOP TB" strategy has given a vision to eliminate TB as a public health problem from the face of this earth by 2050. For this review article, data available at the official websites of WHO; and from the Ministry of Health, Government of India, were consulted, and search engines PubMed; and Google Scholar; were used. Keywords: Bovine TB, DOTS (directly observed treatment-short course), HIV/TB, Multidrug-resistant TB, RNTCP (revised national TB control program), Short course chemotherapy (SCC), TB control program in India, The "Stop TB" strategy, Treatment of TB, Tuberculosis, Zoonosis
How to cite this article:
Sandhu GK. Tuberculosis: Current situation, challenges and overview of its control programs in India. J Global Infect Dis 2011;3:143-50 |
How to cite this URL:
Sandhu GK. Tuberculosis: Current situation, challenges and overview of its control programs in India. J Global Infect Dis [serial online] 2011 [cited 2022 Aug 13];3:143-50. Available from: https://www.jgid.org/text.asp?2011/3/2/143/81691 |
| Introduction | |  |
Tuberculosis (TB) is one of the most ancient diseases of mankind and has co-evolved with humans for many thousands of years or perhaps for several million years. [1] The oldest known molecular evidence of TB was detected in a fossil of an extinct bison (Pleistocene bison), which was radiocarbon dated at 17,870±230 years [2] ; and in 9000, year old human remains which were recovered from a neolithic settlement in the Eastern Mediterranean. [3] Although as early as 1689, it was established by Dr. Richard Morton that the pulmonary form was associated with "tubercles," due to the variety of its symptoms, TB was not identified as a single disease until the 1820s and was eventually named "tuberculosis" in 1839 by J. L. Schφnlein. [4] In 1882, the bacillus causing tuberculosis, Mycobacterium tuberculosis, was discovered by Robert Koch; and for this discovery, he was awarded Nobel prize in physiology or medicine in 1905. [5] Tuberculosis is caused by a group of closely related bacterial species termed Mycobacterium tuberculosis complex. Today the principal cause of human tuberculosis is Mycobacterium tuberculosis. Other members of the M. tuberculosis complex that can cause tuberculosis include M. bovis, M. microti and M. africanum. M. microti is not known to cause TB in humans; infection with M. africanum is very rare, while M. bovis has a wider host range and is the main cause of tuberculosis in other animal species. Humans become infected by M. bovis, usually via milk, milk products or meat from an infected animal. [6],[7] It is estimated that in the pre-antibiotic era, M. bovis was responsible for about 6% of tuberculosis deaths in humans. [8],[9]
In spite of newer modalities for diagnosis and treatment of TB, unfortunately, millions of people are still suffering and dying from this disease. TB is one of the top three infectious killing diseases in the world: HIV/AIDS kills 3 million people each year, TB kills 2 million and malaria kills 1 million. [10] Even though tubercle bacilli was identified nearly 130 years ago, a definitive understanding of pathogenesis of this disease is still deficient. [11],[12] Although it can affect people of any age, individuals with weakened immune systems, e.g., with HIV infection, are at increased risk. Since the immune system in healthy people walls off the causative bacteria, TB infection in healthy people is often asymptomatic. This bacterium lives and multiplies in the macrophages, thus avoiding the natural defense system in the patient's serum. Infection with TB can result in two stages: asymptomatic latent tuberculosis infection (LTBI) or tuberculosis disease. If left untreated, the mortality rate with this disease is over 50%. For this review article, data available at the official websites of world health organization (WHO); from the Ministry of Health, Government of India; through PubMed central and Google scholar; search engines were extensively consulted.
| Global Scenario | | |
According to WHO, TB is a worldwide pandemic. Among the 15 countries with the highest estimated TB incidence rates, 13 are in Africa, while half of all new cases are in six Asian countries, viz., Bangladesh, China, India, Indonesia, Pakistan and Philippines. A WHO fact sheet dated March 2010 [10] on tuberculosis stated that overall one third of the world's population (over 2 billion) is currently infected with the TB bacillus. According to it, every second, someone in the world is newly infected with TB bacilli and 1 in every 10 of these newly infected people will become sick or infectious later in life. Since concurrent infection with HIV weakens the immune system, people with co-infection of HIV and TB are much more likely to develop TB; it is a leading cause of death among HIV-positive people. In Africa, HIV is the single most important factor contributing to the increase in the incidence of TB since 1990. The same fact sheet [10] stated that in 2008, globally speaking, there were 9.37 million new cases of TB, with the African region and the Southeast Asian region (SEAR) having a share of 30% and 34%, respectively. However, the estimated incidence rate in Sub-Saharan Africa is nearly twice that in the SEAR with over 350 cases per 100,000 individuals of the human population. In the same year 2008, an estimated 1.3 million people died from TB. The highest number of deaths was in SEAR, while the highest mortality per capita was in the African region. The global community woke up to this disease when, in 1993, WHO declared TB as a global emergency. It was estimated that by 2004, the world as a whole would have achieved the Millennium Development Goal (MDG) of halting and reversing the incidence to half of its 1990's prevalence and mortality rate. Now the revised time limit to achieve that MDG is by 2015. [13]
Directly observed treatment-short course (DOTS) is an internationally recognized strategy for delivering the basics of TB case-finding and cure. It is not simply a clinical approach to patients, but rather a management strategy for public health systems, including political commitment, case-detection through quality-assured bacteriology, short-course chemotherapy, ensuring patient adherence to treatment, adequate drug supply and sound reporting and recording systems. [13] Worldwide, between 1995 and 2008, a cumulative total of 36 million TB patients were successfully treated in DOTS programs, and up to 6 million deaths were averted. The treatment success rate (~86%) achieved in DOTS cohorts worldwide exceeded the global target of 85% for the first time in 2007. [13]
The southeast asian region (SEAR) of the WHO is critically important from the global perspective. It is home to 25% of the world human population; and with 30% of the world's poor living in this region, it suffers from high burdens of communicable and noncommunicable diseases, against a background of relatively poor health infrastructure. Progress in global health will not be possible without visible progress in this region. Six of the 14 million deaths in this region are caused by communicable diseases, which in turn result in 42% of all the disability-adjusted life years lost. [14],[15]
About 3.6 million persons are estimated to be living with HIV/ AIDS in SEAR. This region is distinguished by a complex, heterogeneous HIV epidemic at different stages, both within countries and across the region. For example, approximately two thirds of the estimated HIV burden in India is in the six states in the south and northeast, which make up only one third of the country's population. In the four states in southern India, the HIV prevalence appears to be slowly decreasing. In Indonesia, where the overall prevalence of HIV is low, three provinces have been reported to have much higher rates of HIV. In other countries, such as Bangladesh and Nepal, increasing HIV prevalence among high-risk groups, such as intravenous drug users (IDUs), has raised concerns about the potential risk of a generalized HIV epidemic in these countries. [15]
| Indian Scenario | | |
In India, TB has been mentioned in the Vedas and the old Ayurvedic scriptures. Historically speaking, fight against TB in India can be broadly classified into three periods: early period, before the discoveries of x-ray and chemotherapy; post-independence period, during which nationwide TB control programs were initiated and implemented; and the current period, during which the ongoing WHO-assisted TB control program is in place.
Early period of TB control
It was marked with non-availability of any chemotherapeutic agents, absence of diagnostic x-ray facilities and lack of any TB control program. This period lasted around middle of the 20 th century. During this period, as no drug or treatments with combinations of drugs were available/ effective against TB, a sanatorium movement originated in Europe and quickly spread worldwide. Popular rationale for sanatoria was that a regimen of rest, good nutrition, open fresh air and high altitude offered the best chance that the sufferer's immune system would "wall off" pockets of pulmonary tuberculosis (TB) infection. In 1863, for the treatment of tuberculosis, Hermann Brehmer opened the world's first sanatorium named Brehmerschen Heilanstalt fόr Lungenkranke0 in the city of Gφrbersdorf (Sokoowsko), Silesia (now Poland).[15]
In India, the first open air sanatorium for treatment and isolation of TB patients was founded in 1906 in Tiluania, near Ajmer city of Rajasthan, followed by the first TB dispensary in Bombay in 1917. [16] By 1925, chest radiology started playing diagnostic role in detecting deep-seated areas of TB consolidation. By 1945, the capability of this apparatus was enhanced to embody the MMR (mass miniature radiography) version. The first genuine success against TB was in immunizing against tuberculosis. Developed from attenuated bovine strain of tuberculosis by Albert Calmette and Camille Guerin in 1906 was BCG (bacillus of Calmette and Guerin); it was first used on humans in France on July 18, 1921. In 1948, with support from WHO and UNICEF, a BCG vaccine production center in Guindy, Madras (now Chennai), was set up. In 1951, India started a mass BCG campaign to control TB. This was the first nationwide campaign against TB [17] ; and for the first time in the history of India, message of health and prevention of disease was taken to the remotest parts of the country.
Post-independence initial nationwide TB control programs
This period can be conveniently subdivided into the following two phases:
District TB program
In 1961, District Tuberculosis Program was prepared by the Indian government, and Anantapur district in Andhra Pradesh state was the first model district TB center (DTC). This program was aimed at integration of TB control schemes with the existing government health services to reduce the TB problem in the community as economically as possible. [18] Shortly after establishing the Anantapur DTC, it became evident that although case-finding could be done at any place without difficulty, the major problem in the fight against TB was that of keeping the patients on continuous treatment until cure was achieved. [19] Using this district TB center model, in 1962, the Indian government launched the National TB Control Program (NTCP).
Era of short-course chemotherapy
In the middle of the 20 th century, around the time India gained independence in 1947, effective drugs against TB started becoming available (Streptomycin: 1944, PAS: 1946, Thiacetazone: 1950, Isoniazid: 1952 and Rifampicin: 1966). [20] In 1956, under the auspices of the Indian Council of Medical Research (ICMR), the government of Chennai state, the WHO and the British Medical Research Council (BMRC), the Indian government established the Tuberculosis Research Center (TRC) in Chennai. This center provided information on the mass domiciliary application of chemotherapy in the treatment of pulmonary TB. In 1959, National Tuberculosis Institute (NTI) was established at Bangalore to evolve, through research, a practicable TB program that could be applied in all parts of the country by training medical and paramedical workers to efficiently apply proven methods in rural and urban areas. [21]
Chemotherapy for TB underwent revolutionary changes in the seventies owing to the availability of two well-tolerated and highly effective drugs, Rifampicin and Pyrazinamide. These drugs allowed short-course chemotherapy (SCC) and made it possible to simplify treatment and reduce its duration. Discovery of Rifampicin in 1967 is considered to be one of the greatest achievements in the history of development of anti-TB drugs. Since its discovery, no new drug has been discovered yet that is as efficacious as Rifampicin against TB.
Current WHO-assisted ongoing TB control program
In 1992, Government of India, together with the WHO and the Swedish International Development Agency (SIDA), reviewed the national program and concluded that it suffered from managerial weaknesses, inadequate funding, over-reliance on x-ray, nonstandard treatment regimens, low rates of treatment compliance and completion and lack of systematic information on treatment outcomes. [22] Around the same time, in 1993, WHO declared TB to be a global emergency and devised the DOTS strategy and recommended that all countries adopt this strategy. This strategy was built on five pillars, viz., political commitment and continued funding for TB control programs, diagnosis by sputum smear examinations, uninterrupted supply of high-quality anti-TB drugs, drug intake under direct observation and accurate reporting and recording of all registered cases.
World Bank acknowledged that the DOTS strategy was the most economical health intervention and agreed to provide credit assistance for the NTCP, initially for the coverage of a population of 271 million persons, which was later revised to cover a population of 730 million persons. Presently, other bilateral and multilateral agencies, Danish International Development Agency (DANIDA), Department for International Development (DFID), US Agency for International Development (USAID), Global Fund to Fight HIV/AIDS, Tuberculosis and Malaria (GFATM), Global Drug Facility (GDF) and WHO are providing invaluable support to the program. The Global Fund to Fight HIV/AIDS, Tuberculosis and Malaria is the single biggest source of external funding for TB control. [23]
To give new thrust and to revitalize the NTCP, with assistance from the above-mentioned international agencies, in 1997, the Revised National TB Control Program (RNTCP) was launched. [24] It formulated and adopted the internationally recommended DOTS strategy, as the most systematic and cost-effective approach to revitalize the TB control program in India. Political and administrative commitment to ensure the provision of organized and comprehensive TB control services; reliable and early diagnosis through smear microscopy; an uninterrupted supply of good-quality anti-TB drugs; effective and patient-friendly treatment with short-course chemotherapy (SCC) given under direct observation; and accountability through proper reporting and recording and through effective supervision was heavily emphasized. [25] Today, India's DOTS program is the fastest-expanding and the largest program in the world in terms of patients initiated on treatment; and the second largest, in terms of population coverage.
| HIV and TB | | |
People who are HIV-positive and infected with TB are 20 to 40 times more likely to develop active TB than people not infected with HIV living in the same country. [26] TB is a leading cause of death in people with HIV infection, accounting for more than a quarter of the 2 million AIDS deaths in 2008; it is the commonest HIV-associated opportunistic disease in the world [27] ; it accelerates HIV disease progression, increasing infectivity and reducing HIV treatment efficacy. [28],[29]
In India, there were 2.5 million people living with HIV and AIDS (PLHIV) at the end of 2007, while the incidence of TB was approximately 1.8 million cases per year. [30] The interaction between HIV and TB in persons co-infected with HIV and TB is bidirectional and synergistic. The level of immunosuppression determines clinical presentation of the resulting disease. [31],[32] Pulmonary involvement occurs in about 75% of all HIV/TB-infected patients. [33],[34] It was observed that the most frequent extra-pulmonary form of TB in HIV-positive people is that with involvement of the lymph nodes, with cervical region being the commonest. [35] Co-infection of HIV and TB also results in more rapid development of MDR-TB. [36],[37]
A national policy to coordinate common activities for HIV/AIDS and TB has been formulated by the National AIDS Control Organization and the Central TB Division. TB and TB/HIV interventions are reciprocally included in the national policies of both programs. [30] Among the 1.5 million TB cases reported under the national program in 2008, an estimated 73,720 cases were HIV-infected. Implementation of the revised "national framework of joint TB/HIV collaborative activities" began in early 2008, and interventions now cover the entire country. An "intensified TB/HIV package" initiated in 2008 is now being implemented in 11 states and in districts of other states with high HIV prevalence, covering a total population of over 400 million. Indian government plans to cover the entire country with the intensified package by 2012. [21]
Current guidelines (National AIDS Control Organization, 2007) recommend that irrespective of HIV status of the patient, TB requires a minimum of 6 months of treatment - with 4 drugs (including Rifampin) in the intensive phase and 2 drugs in the continuation phase. [30] Treatment consists of Isoniazid (INH), Rifampicin (RIF), Ethambutol (EMB) and Pyrazinamide (PYZ) for 2 months followed by INH and RIF for 4 months, given either daily or intermittently. It further classifies the currently available antiretroviral (ART) agents as follows: nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase inhibitors, chemokine receptor antagonists and entry (fusion) inhibitors. A reduction by 80% in incident TB in HAART (highly active antiretroviral therapy)-treated patients (treated with a combination of at least 3 ART drugs) was demonstrated as compared to ART-naοve HIV-infected persons in Brazil. [38] Regimens recommended for use in India for HIV/TB patients are a combination of 2 NRTIs with Efavirenz or, less commonly, Nevirapine. The NRTI combinations used commonly are Zidovudine with Lamivudine; Stavudine with Lamivudine; Tenofovir with Lamivudine; and rarely "Abacavir with Lamivudine" or "Didanosine with Lamivudine." [30]
A commonly observed side effect of HAART is immune reconstitution inflammatory syndrome (IRIS), which is defined as transient worsening of existing symptoms, signs or radiographic manifestations or transient appearance of new symptoms, signs or radiographic manifestations after initiation of HAART. Tuberculosis is the most frequent pathogen associated with IRIS, of which, lymph node enlargement is the commonest manifestation. In one study, the incidence of IRIS in TB alone was 2%; with HIV co- infection, it was 7%; and in those started on HAART, it was 36%. [39]
Surveillance for HIV infection among TB patients has been previously conducted in special surveys, and now relies upon routine reporting of HIV status of TB patients. Based on pilot-testing of decentralized delivery of co-trimoxazole preventive therapy (CPT) for HIV-infected TB patients in three high-HIV-prevalence districts of Andhra Pradesh, CPT for HIV-infected TB patients has been included in the national policies. PLHIV are eligible for free HIV care at a network of antiretroviral treatment (ART) centers. These centers are located in medical colleges, mainly staffed and operated by the State AIDS Control Societies, and a few are situated within the facilities of private or NGO partners. As of September 2009, 217 ART centers were operating in the country, in addition to ten Regional Centers of Excellence providing state-of-the-art services for PLHIV. [30]
| Current Challenges | | |
Even today in India, two deaths occur every three minutes from TB. Major challenges to control TB in India include poor primary health-care infrastructure in rural areas of many states; unregulated private health care leading to widespread irrational use of first-line and second-line anti-TB drugs; spreading HIV infection; poverty; lack of political will; and, above all, corrupt administration. A collaborative effort is in progress between NTCP and National Rural Health Mission (NRHM), which is a reform initiative of which the goal is to improve primary health care in rural areas. In addition to this, NTCP has established several initiatives in coordination with the private sector and the Indian Medical Association (IMA) to improve TB care.
Surprisingly, in India, people are still under the impression that TB is a disease of poor people, mostly of those living in slums. The rich and affluent persons need to know that their cooks/servants/drivers can be asymptomatic carriers of this deadly disease, right in their mansions, and hence they can potentially get infected with TB even without stepping into these slums. The consumption of unpasteurized milk or dairy products made from raw milk is another potential source of TB for humans, as there is ample evidence that bovine TB (Mycobacterium bovis) gets transmitted to humans. [6],[7]
| Multidrug-Resistant Tuberculosis | | |
M. tuberculosis strains that are resistant to the two most potent anti-TB drugs, viz., Isoniazid and Rifampicin, are termed as multidrug-resistant TB (MDR-TB) strains. Extensively drug-resistant TB (XDR-TB) is a form of TB caused by bacteria that are resistant to Isoniazid and Rifampicin (i.e., MDR-TB), as well as to any fluoroquinolone and any of the second-line anti-TB injectable drugs (amikacin, kanamycin or capreomycin). These forms of TB do not respond to the standard six-month treatment with first-line anti-TB drugs and can take up to two years or more to treat with drugs that are less potent, more toxic and much more expensive. [40] Both MDR-TB and XDR-TB are the emerging threats to the success of anti-TB programs.
In the words of Sir John Crofton, whose pioneering work in the use of combination drug therapy for the treatment of tuberculosis has resulted in countless lives saved, "The greatest disaster that can happen to a patient with tuberculosis is that his organisms become resistant to two or more of the standard drugs. The development of drug resistance may be a tragedy not only for the patient himself but also for others, for he can infect other people with his drug-resistant organisms." [41]
Drug resistance may be broadly classified as primary and acquired. Drug resistance in a patient who has never received anti-TB treatment previously is termed as primary resistance. Acquired resistance is that which occurs as a result of specific previous treatment. WHO and the IUATLD have now replaced the term primary resistance with the term drug resistance among new cases; and acquired resistance, with the term drug resistance among previously treated cases.[42],[43] The emergence of drug resistance in TB patients is mostly a result of deficient or deteriorating TB control programs. Factors related to the development of drug resistance include the following: inadequate or inefficient administration of effective treatment; poor case holding; use of substandard drugs; inadequate or irregular drug supply; ignorance of health care workers in the treatment and control of TB; interruption of chemotherapy due to side effects; non-adherence of patients to the prescribed regimens; availability of anti-TB drugs without prescription; illiteracy; low socioeconomic status of patients; massive bacillary load; laboratory delays in identification and susceptibility-testing of M. tuberculosis isolates; and the lack of the use of uniform laboratory methodology and quality control measures. [44]
As per WHO guidelines, [40],[45] the current protocol for treatment of MDR-TB recommends standardized treatment regimen for empirical treatment in patients who have previously received only first-line TB drugs. The standardized regimen includes mixture of essential drugs - Streptomycin, Pyrazinamide, Ethambutol and Thioacetazone; and second-line drugs - Aminoglycosides (Kanamycine, Amikacin, capreomycine), Thioamides (Ethionamide, Prothionamide), Fluoroquinolones (Ofloxacin, Ciprofloxacin), Cycloserine/Terizidone and Para-aminosalicylic acid. Surgery should be considered for a patient with bacilli resistant, or probably resistant, to all except two or three relatively weak drugs. Unfortunately many such patients will have too extensive disease and/or too poor lung function for surgery to be possible. If the patient has a large localized cavity with little other disease, reasonable lung function and only two or three (weak) drugs available, surgery should be seriously considered.
Since current drug resistance data have a bearing on the design of the treatment regimens and policies, reliable information on these at the national level is both urgently and regularly needed. In the year 2005, 0.04% of the TB cases in India were diagnosed and reported as MDR-TB, which rose to 0.15% (~4 times) in the year 2007. Services to control MDR-TB are now available at designated sites in six states, with culture and DST facilities offered in five state-level laboratories. Weak laboratory capacity is a major barrier to scaling-up MDR-TB services. Collaborative TB/HIV activities have considerable scope for expansion. Government should ensure and promote rational use of anti-TB drugs outside the revised national TB control program. [46]
Since available data from India cover only a small portion of this vast country, there is need for continuous surveying of drug resistance by a network of investigators in different regions of the country, by employing a common protocol, with an emphasis on quality control, which will serve as a useful parameter in the evaluation of current and past chemotherapy programs.
| Conclusions | | |
As is evident from the above discussion, we have come a long way in our fight against this deadly disease, but as the famous English poet Robert Frost said, "… miles to go before I sleep", we still have miles to go before we will make this planet TB free. WHO with its "STOP TB" strategy has given a vision to eliminate TB as a public health problem from the face of this earth by 2050. [46] In order to intensify our fight against this deadly disease, we need to further strengthen our surveillance programs to accurately estimate the burden of all kinds of TB (childhood, HIV/TB, MDR-TB). There is dire need to regulate the rational use of first- and second-line anti-TB drugs. They should absolutely not be sold as over the counter drugs. In India and in other developing countries, local governments should put in and encourage wholehearted efforts for local manufacturing of anti-TB drugs, thus resulting in more efficient monitoring of their manufacturing and quality control standards. Monitoring the quality of products available in the marketplace should involve identifying products that are defective because of poor manufacturing practices; deteriorated because of inadequate distribution and storage; and adulterated, tampered or counterfeit because of vested interests. Many studies have documented the circulation of counterfeit and substandard medicines, especially antimalarials, in developing countries. [47],[48],[49] If counterfeit drugs belonging to this category are circulating in the markets, then there is every reason to assume that the counterfeit anti-TB drugs are also available in these markets.
Working association between physicians; private sector; religious bodies; and other local nonprofit organizations, e.g., Lions Club, Rotary International, should be strengthened for better dissemination of awareness about diagnosis, management and control of this disease. Existing diagnostic laboratories need to be strengthened with routine training/refresher courses for the involved personnel for better utilization of these already scarce resources. Better diagnostic tests for quick screening of this disease at field level should be developed and made available at the grass-root level. The links between primary health centers and DOTS centers should be strengthened, and special attention should be given to prioritizing the groups which need to be followed first; utilizing human resources of related public health programs, e.g., programs for HIV/malaria; promoting development of new drugs and vaccines against TB; and discouraging the use of homeopathy medicines for treating TB and HIV. [50]
To eliminate the potential zoonotic sources of TB, pasteurization of milk before marketing and organized goat/sheep abattoirs should be made mandatory under law; where milk samples and carcasses can be routinely tested/examined for TB; and the cause of TB possibly traced to the infected herds. Vaccination of our livestock against TB and routine screening of livestock (e.g., on a yearly basis at the farms and also at the animal fairs) should be made mandatory. Our fight against TB will be incomplete without considering this zoonotic aspect of this deadly disease.
| References | | |
| 1. | Hirsh AE, Tsolaki AG, DeRiemer K, Feldman MW, Small PM. Stable association between strains of Mycobacterium tuberculosis and their human host populations. Proc Natl Acad Sci USA 2004;101:4871-6. 
[PUBMED] [FULLTEXT] |
| 2. | Rothschild BM, Martin LD, Lev G, Bercovier H, Bar-Gal GK, Greenblatt CL, et al. Mycobacterium tuberculosis Complex DNA from an Extinct Bison Dated 17,000 Years before the Present. Clin Infec Dis 2001;33:305-11.
|
| 3. | Hershkovitz I, Donoghue HD, Minnikin DE, Besra GS, Lee OY-C, Gernaey AM, et al. Detection and molecular characterization of 9000-year-old Mycobacterium tuberculosis from a neolithic settlement in the Eastern Mediterranean. PLoS ONE 2008;3:e3426.
|
| 4. | News-medical.net [Internet]. History of Tuberculosis. Available from: http://www.news-medical.net/health/History-of-Tuberculosis.aspx [Last cited on 2010 Oct 15].
|
| 5. | Nobelprize.org [Internet]. Sweden: The Nobel Prize in Physiology or Medicine 1905: Robert Koch; c2010 Available from: http://nobelprize.org/nobel_prizes/medicine/laureates/1905/koch.html [Last cited on 2010 Oct 15].
|
| 6. | Prasad H, Singhal A, Mishra A, Shah N, Katoch V, Thakral S, et al. Bovine tuberculosis in India: Potential basis for zoonosis. Tuberculosis 2005;85:421-8.
|
| 7. | Srivastava K, Chauhan DS, Gupta P, Singh HB, Sharma VD, Yadav VS, et al. Isolation of Mycobacterium bovis and M. tuberculosis from cattle of some farms in north India-Possible relevance in human health. Indian J Med Res 2008;128:26-31.
[PUBMED]  |
| 8. | Hardie RM, Watson JM. Mycobacterium bovis in England and Wales: Past, present and future. Epidemiol Infect 1992;109:23-33.
[PUBMED] [FULLTEXT] |
| 9. | O′Reilly LM, Daborn CJ. The epidemiology of Mycobacterium bovis infections in animals and man: A review. Tuber Lung Dis 1995;76:S1-46.
|
| 10. | World Health Organization. Fact Sheet No.104: Tuberculosis. Geneva: WHO; 2010 Available from: http://www.who.int/mediacentre/factsheets/fs104/en/print.html [Last cited on 2010 Oct 15].
|
| 11. | Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998;393:537-44.
[PUBMED] [FULLTEXT] |
| 12. | Brosch R, Gordon SV, Marmiesse M, Brodin P, Buchrieser C, Eiglmeier K, et al. A new evolutionary scenario for the Mycobacterium tuberculosis complex. Proc Natl Acad Sci U S A 2002;99:3684-9.
[PUBMED] [FULLTEXT] |
| 13. | World Health Organization. THE GLOBAL PLAN TO STOP TB 2006-2015: PART I Strategic directions. Geneva: WHO; 2006 Available from: http://www.searo.who.int/LinkFiles/TB_Day_Kit_The_Global_Plan_to_Stop_TB_2006-2015.pdf [Last cited on 2010 Oct 15].
|
| 14. | World Health Organization. TB/HIV in the South-East Asia Region Status Report. Regional Meeting of National TB Programme Managers, WHO/SEARO, New Delhi, India; 2-5 Nov 2009. Geneva: WHO; 2009. p. 2-3.
|
| 15. | McCarthy OR. The key to the sanatoria. J R Soc Med 2001;94:413-7.
[PUBMED] [FULLTEXT] |
| 16. | Proceedings of the Tuberculosis Association of India. New Delhi, India: Tuberculosis Association of India; 1939.
|
| 17. | Proceedings of 5 th All India BCG Conference; 1962; Bangalore, India.
|
| 18. | Agarwal SP, Vijay S, Kumar P, Chauhan LS. The history of Tuberculosis Control in India: Glimpses through decades. In: Agarwal SP, Chauhan LS, editors. Tuberculosis Control in India. New Delhi, India: Directorate General of Health Services, Ministry of Health and Family Welfare.2005. p. 15-22.
|
| 19. | Indian Council of Medical Research. Tuberculosis in India: A national sample survey 1955-58. Technical report series. New Delhi, India: Indian Council of Medical Research; 1959.
|
| 20. | Sikand BK, Pamra SP. Domicilliary treatment-results of antibiotic therapy. Proceedings of the 13 th TB Workers Conference; 1956; Trivandrum, India. India: TB Association of Trivandrum; 1956. p. 179-213.
|
| 21. | Ntiindia.kar.nic.in [Internet]. India: National Tuberculosis Institute, Bangalore, India; Available from: http://ntiindia.kar.nic.in/aboutus.htm [Last updated on 2010 Jan 21; cited on 2010 Oct 15].
|
| 22. | World Health Organization. Tuberculosis programme review-India. Geneva: WHO; 1992.
|
| 23. | Theglobalfund.org [Internet]. The Global Fund to fight AIDS, Tuberculosis and Malaria; Available from: http://www.theglobalfund.org/en/commitmentsdisbursements/?lang=eng c2010 [Last cited on 2010 Oct 15].
|
| 24. | World Health Organization. Joint TB Programme Review-India: WHO, SEARO-TB-224. Geneva: WHO; 2000.
|
| 25. | Khatri GR, Frieden TR. The status and prospects of tuberculosis control in India. Int J Tuberc Lung Dis 2000;4:193-6.
[PUBMED] [FULLTEXT] |
| 26. | World Health Organization. Monograph on integrated monitoring of TB/HIV- a case study in Malawi. Geneva: WHO; 2009.
|
| 27. | Lawn SD. Tuberculosis and HIV co-infection. Medicine 2005;33:112-3.
|
| 28. | Chaovavanich A, Chottanapand S, Manosuthi W, Sungkanuparph S, Thongyen S. Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr 2006;43:42-6.
|
| 29. | Dagnra AY, Adjoh K, Tchaptchet Heunda S, Patassi AA, Sadzo D, Hetsu F, et al. Prevalence of HIV-TB co-infection and impact of HIV infection on pulmonary tuberculosis outcome in Togo. Bull Soc Pathol Exot 2010 [In Press].
|
| 30. | National AIDS Control Organization. Antiretroviral therapy guidelines for HIV-infected adults and adolescents including post-exposure prophylaxis (Section A7). New Delhi, India: National AIDS Control Organization; 2007.
|
| 31. | Kumarasamy N, Vallabhaneni S, Flanigan TP, Mayer KH, Solomon S. Clinical profile of HIV in India. Indian J Med Res 2005;121:377-94.
|
| 32. | Sharma SK, Mohan A, Kadhiravan T. HIV-TB coinfection: Epidemiology, diagnosis and management. Indian J Med Res 2005;121:550-67.
|
| 33. | Deivanayagam CN, Rajasekaran S, Senthilnathan V, Krishnarajasekhar R, Raja K, Chandrasekar C, et al. Clinicoradiological spectrum of tuberculosis among HIV sero-positives a Tambaram study. Indian J Tuber 2001;48:123-7.
|
| 34. | Ahmad Z, Shameem M. Manifestations of Tuberculosis in HIV Infected Patients. J Indian Acad Clin Med 2005;6:302-5.
|
| 35. | Arora VK, Kumar SV. Pattern of opportunistic pulmonary infections in HIV sero-positive subjects: Observations from Pondicherry, India. Indian J Chest Dis Allied Sci 1999;41:135-44.
[PUBMED] |
| 36. | Demissie M, Lemma E, Gebeyehu M, Lindtjorn B. Sensitivity to anti-tuberculosis drugs in HIV-positive and -negative patients in Addis Ababa. Scand J Infect Dis 2001;33:914-9.
[PUBMED] |
| 37. | Kebede D, Mitike G, Yeneneh H. HIV Infection and Antituberculosis Drug Resistance among Pulmonary Tuberculosis Patients in Harar Tuberculosis Center, Ethiopia. East African Med J. 1997;74:154-7. Available from: http://cat.inist.fr/?aModele=afficheNandcpsidt=2791912 [Last cited 2010 Oct 21]
|
| 38. | Miranda A, Morgan M, Jamal L, Laserson K, Barreira D, Silva G, et al. Impact of antiretroviral therapy on the incidence of tuber-culosis: The Brazilian experience, 1995-2001. PLoS One 2007;2:e826.
[PUBMED] [FULLTEXT] |
| 39. | Narita M, Ashkin D, Hollender ES, Pitchenik AE. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am Crit Care 1998;158:157-61.
|
| 40. | Crofton J, Chaulet P, Maher D. Guidelines for the management of drug-resistant Tuberculosis. Geneva: WHO; 1997. p. 31-7.
|
| 41. | Crofton J. Chemotherapy of pulmonary tuberculosis. Br Med J 1959;1:1610-4.
[PUBMED] [FULLTEXT] |
| 42. | World Health Organization. The WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance. Anti-tuberculosis drug resistance in the world. Report No. 2. Geneva: WHO; 2000.
|
| 43. | World Health Organization. The WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance. Report No. 3. Geneva: WHO; 2003.
|
| 44. | Paramasivan CN. Surveillance of Drug resistance in India. In: Agarwal SP, Chauhan LS, editors. Tuberculosis Control in India. India. New Delhi, India: Directorate General of Health Services, Ministry of Health and Family Welfare; 2005. p. 47-52.
|
| 45. | World Health Organization. Guidelines for the Programmatic Management of Drug-resistant Tuberculosis: Emergency Update 2008 (WHO/HTM/TB/2008.402). Geneva: WHO; 2008.
|
| 46. | World Health Organization. Global Tuberculosis Report. Geneva: WHO; 2009.
|
| 47. | Atemnkeng MA, DeCock K, Plaizier-Vercammenn J. Quality control of active ingredients in artemisinin-derivative antimalarials within Kenya and DR Congo. Trop Med Int Health 2007;12:68-74.
|
| 48. | Bate R, Coticelli P, Tren R, Attaran A. Antimalarial drug quality in the most severely malarious parts of Africa: A six country study. PLoS One 2008;3:e2132.
[PUBMED] [FULLTEXT] |
| 49. | Onwujekwe O, Kaur H, Dike N, Shu E, Uzochukwu B, Hanson K, et al. Quality of Anti-malarial drugs provided by public and private healthcare providers in South-East Nigeria. Malar J 2009;8:22.
[PUBMED] [FULLTEXT] |
| 50. | ANI. Homeopathy doesn′t help in HIV, TB, Malaria. The Times of India. India: c2010. Available from: http://timesofindia.indiatimes.com/life-style/health-fitness/health/Homeopathy-doesnt-help-in-HIV-TB-malaria/articleshow/4918285.cms [Last cited on 2009 Aug 25].
|
Correspondence Address:
Gursimrat K Sandhu
Faculty of Medicine, Lund University, Lund
Sweden
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0974-777X.81691
|
|
| This article has been cited by | | 1 |
Computational design of MmpL3 inhibitors for tuberculosis therapy |
|
| R. Chaitra, Rohit Gandhi, N. Jayanna, Sachin Satyanath, Parasuraman Pavadai, Manikanta Murahari | | Molecular Diversity. 2022; | | [Pubmed] | [DOI] | | | 2 |
One-step preparation of N-doped grapheme quantum dots with high quantum yield for bioimaging and highly sensitive electrochemical detection of isoniazid |
|
| S. Sivaselvam, C. Viswanathan, N. Ponpandian | | Biomaterials Advances. 2022; : 212731 | | [Pubmed] | [DOI] | | | 3 |
Association of IRGM promoter region polymorphisms and haplotype with pulmonary tuberculosis in Pakistani (Punjab) population |
|
| Ayesha Zafar, Mohsin Shafiq, Basharat Ali, Wolfgang Sadee, Abdul Rauf Shakoori, Farah Rauf Shakoori | | Tuberculosis. 2022; : 102233 | | [Pubmed] | [DOI] | | | 4 |
Development of peptide vaccine candidate using highly antigenic PE-PGRS family proteins to stimulate the host immune response against Mycobacterium tuberculosis H37Rv: an immuno-informatics approach |
|
| Ajit Kumar, Priyanka Sharma, Akanksha Arun, Laxman S. Meena | | Journal of Biomolecular Structure and Dynamics. 2022; : 1 | | [Pubmed] | [DOI] | | | 5 |
Anti-mycobacterial activity of heat and pH stable high molecular weight protein(s) secreted by a bacterial laboratory contaminant |
|
| Md. Sajid Hussain, Atul Vashist, Mahadevan Kumar, Neetu Kumra Taneja, Uma Shankar Gautam, Seema Dwivedi, Jaya Sivaswami Tyagi, Rajesh Kumar Gupta | | Microbial Cell Factories. 2022; 21(1) | | [Pubmed] | [DOI] | | | 6 |
Determinants of delayed tuberculosis treatment among patients in Selangor: A study protocol |
|
| Punitha Makeswaran, Shamsul Azhar Shah, Nazarudin Safian, Nor Asiah Muhamad, Abdul Aziz Harith, Seyed Ehtesham Hasnain | | PLOS ONE. 2022; 17(4): e0266746 | | [Pubmed] | [DOI] | | | 7 |
2 Receptor Specific Ligand Conjugated Nanocarriers: An Effective Strategy
for Targeted Therapy of Tuberculosis |
|
| Pratiksha Prabhu, Trinette Fernandes, Mansi Damani, Pramila Chaubey, Shridhar Narayanan, Sujata Sawarkar | | Current Drug Delivery. 2022; 19(8): 830 | | [Pubmed] | [DOI] | | | 8 |
Interaction of Host Pattern Recognition Receptors (PRRs) with Mycobacterium
Tuberculosis and Ayurvedic Management of Tuberculosis: A Systemic
Approach |
|
| Nirmaladevi Ponnusamy, Mohanapriya Arumugam | | Infectious Disorders - Drug Targets. 2022; 22(2) | | [Pubmed] | [DOI] | | | 9 |
Population Pharmacokinetics and Pharmacodynamics of Isoniazid and its Metabolite Acetylisoniazid in Chinese Population |
|
| Bing Chen, Hao-Qiang Shi, Meihua Rose Feng, Xi-Han Wang, Xiao-Mei Cao, Wei-Min Cai | | Frontiers in Pharmacology. 2022; 13 | | [Pubmed] | [DOI] | | | 10 |
Novel In Silico Insights into Rv1417 and Rv2617c as Potential Protein Targets: The Importance of the Medium on the Structural Interactions with Exported Repetitive Protein (Erp) of Mycobacterium tuberculosis |
|
| Margot Paco-Chipana, Camilo Febres-Molina, Jorge Alberto Aguilar-Pineda, Badhin Gómez | | Polymers. 2022; 14(13): 2577 | | [Pubmed] | [DOI] | | | 11 |
AN INSIGHT INTO PRIVILEGED SCAFFOLDS IN TUBERCULOSIS: DEVELOPMENTAL ASPECTS AND IMPLICATIONS IN DRUG DESIGN |
|
| Rani. A. Shinde, Vasanti. M. Suvarna, Arundhati. N. Abhyankar | | Indian Drugs. 2022; 59(01): 7 | | [Pubmed] | [DOI] | | | 12 |
Breast Tuberculosis: A Report of Two Cases |
|
| Meghraj Kundan, Puthangot Aswin, Garima Tyagi, Mainak Ghosh | | International Journal of Infection. 2022; 9(3) | | [Pubmed] | [DOI] | | | 13 |
Need-based training of community health officers for tuberculosis care in Ahmednagar district of Maharashtra, India: A before and after study |
|
| MandarPadmakar Baviskar, Ankita Sinha, ShubhadaS Javadekar, Rajvir Bhalwar | | Journal of Education and Health Promotion. 2021; 10(1): 322 | | [Pubmed] | [DOI] | | | 14 |
Quercetin Loaded Rifampicin-Floating Microspheres for Improved Stability and In-vitro Drug Release |
|
| Prashant Lakshaman Pingale, Sunil Vishwanath Amrutkar | | Pharmacophore. 2021; 12(3): 95 | | [Pubmed] | [DOI] | | | 15 |
“TUBERCULOSIS – A COMMON GRANULOMATOUS DISEASE AT UNCOMMON SITES: A COMPREHENSIVE HISTOCYTOLOGICAL STUDY IN A TERTIARY CARE HOSPITAL OF CENTRAL INDIA” |
|
| Anki Saluja, Rashmi Gupta, Chitrangi P. Barpande, B. P. Singh | | INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH. 2021; : 65 | | [Pubmed] | [DOI] | | | 16 |
ISONIAZID MONORESISTANCE : THE NEW CHALLENGE IN DRUG RESISTANT TUBERCULOSIS |
|
| Paulami Palchowdhury, Anindita Rakshit, Aitihya Chakraborty, Banya Chakraborty | | INDIAN JOURNAL OF APPLIED RESEARCH. 2021; : 38 | | [Pubmed] | [DOI] | | | 17 |
A Rare Case of Tuberculosis Cutis Colliquative |
|
| Shravya Rimmalapudi, Amruta D. Morey, Bhushan Madke, Adarsh Lata Singh, Sugat Jawade | | Journal of Evolution of Medical and Dental Sciences. 2021; 10(5): 305 | | [Pubmed] | [DOI] | | | 18 |
State Feedback and Synergetic controllers for tuberculosis in infected population |
|
| Muhammad Bilal, Iftikhar Ahmad, Sheraz Ahmad Babar, Khurram Shahzad | | IET Systems Biology. 2021; 15(3): 83 | | [Pubmed] | [DOI] | | | 19 |
Scenario of Tuberculosis in India |
|
| Jyoti Priyadarshini Shrivastava, Alok Shrivastava | | Journal of Lung, Pulmonary & Respiratory Research. 2021; 8(2): 24 | | [Pubmed] | [DOI] | | | 20 |
Tuberculosis amidst COVID-19 pandemic in India: unspoken challenges and the way forward |
|
| Mainak Bardhan, Mohammad Mehedi Hasan, Ishita Ray, Anusua Sarkar, Priyanka Chahal, Sudhan Rackimuthu, Mohammad Yasir Essar | | Tropical Medicine and Health. 2021; 49(1) | | [Pubmed] | [DOI] | | | 21 |
Hybrid PET/MRI findings in a case of pulmonary and extra-pulmonary tuberculosis associated with motor-neuron disease-like illness—a coincidence or a causation?: a case report |
|
| Sameer Peer, Chandana Nagaraj, Sandhya Mangalore | | Egyptian Journal of Radiology and Nuclear Medicine. 2021; 52(1) | | [Pubmed] | [DOI] | | | 22 |
In-vitro Anti-Tuberculosis, Anti-Efflux Pumps and Anti-Biofilm Effects of Crinum Asiaticum Bulbs |
|
| Michael Ofori, Cynthia Amaning Danquah, Selase Ativui, Peace Doe, Williams Adu Asamoah | | Biomedical and Pharmacology Journal. 2021; 14(4): 1905 | | [Pubmed] | [DOI] | | | 23 |
Computational exploration and anti-mycobacterial activity of potential inhibitors of Mycobacterium tuberculosis acetyl coenzyme A carboxylase as anti-tubercular agents |
|
| J. Kuldeep, S.K. Sharma, B.N. Singh, M.I. Siddiqi | | SAR and QSAR in Environmental Research. 2021; 32(3): 191 | | [Pubmed] | [DOI] | | | 24 |
Long-term exposure to indoor air pollution and risk of tuberculosis |
|
| Vidhiben Patel, Andrew Foster, Alison Salem, Amit Kumar, Vineet Kumar, Biplab Biswas, Mehdi Mirsaeidi, Naresh Kumar | | Indoor Air. 2021; 31(3): 628 | | [Pubmed] | [DOI] | | | 25 |
Identification of bioactive natural compounds as efficient inhibitors against Mycobacterium tuberculosis protein-targets: A molecular docking and molecular dynamics simulation study |
|
| Sravan Kumar Miryala, Soumya Basu, Aniket Naha, Reetika Debroy, Sudha Ramaiah, Anand Anbarasu, Saravanan Natarajan | | Journal of Molecular Liquids. 2021; 341: 117340 | | [Pubmed] | [DOI] | | | 26 |
Is Mycobacterium tuberculosis carcinogenic to humans? |
|
| Deodutta Roy, Nasreen Z. Ehtesham, Seyed Ehtesham Hasnain | | The FASEB Journal. 2021; 35(9) | | [Pubmed] | [DOI] | | | 27 |
Mitigating the externality of diseases of poverty through health aid |
|
| Kamal Jnawali, Michael G. Tyshenko, Tamer Oraby | | Royal Society Open Science. 2021; 8(10) | | [Pubmed] | [DOI] | | | 28 |
Modeling and analysis of barriers in controlling TB: developing countries' perspective |
|
| Palka Mittal, Puneeta Ajmera, Vineet Jain, Gaurav Aggarwal | | International Journal of Health Governance. 2021; ahead-of-p(ahead-of-p) | | [Pubmed] | [DOI] | | | 29 |
Mycobacterium enoyl acyl carrier protein reductase (InhA): A key target for antitubercular drug discovery |
|
| Mayuri S. Prasad, Ritesh P. Bhole, Pramod B. Khedekar, Rupesh V. Chikhale | | Bioorganic Chemistry. 2021; 115: 105242 | | [Pubmed] | [DOI] | | | 30 |
Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis |
|
| Satyaveni Malasala, Md Naiyaz Ahmad, Ravikumar Akunuri, Manjulika Shukla, Grace Kaul, Arunava Dasgupta, Y.V. Madhavi, Sidharth Chopra, Srinivas Nanduri | | European Journal of Medicinal Chemistry. 2021; 212: 112996 | | [Pubmed] | [DOI] | | | 31 |
Status and challenges for tuberculosis control in India – Stakeholders' perspective |
|
| Gargi Thakur, Shalvi Thakur, Harshad Thakur | | Indian Journal of Tuberculosis. 2021; 68(3): 334 | | [Pubmed] | [DOI] | | | 32 |
Tuberculous ARDS is associated with worse outcome when compared with non-tuberculous infectious ARDS |
|
| Thomas Isaiah Sudarsan, Lovely Thomas, Abhishek Samprathi, Binila Chacko, Alice Mathuram, Tina George, Gunasekaran Karthik, Sudha Jasmine Rajan, Ronald Albert Benton Carey, Gowri Mahasampath, John Victor Peter | | Journal of Critical Care. 2021; 61: 138 | | [Pubmed] | [DOI] | | | 33 |
Analysis of CD4 and CD8 expression in multidrug-resistant tuberculosis infection with diabetes mellitus: An experimental study in mice |
|
| Heidy Agustin, Muhammad Nasrum Massi, Irawati Djaharuddin, Agus Dwi Susanto, Andi Asadul Islam, Mochammad Hatta, Agussalim Bukhari, Nur Ahmad Tabri, Arif Santoso, Ilhamjaya Patellongi | | Annals of Medicine and Surgery. 2021; 68: 102596 | | [Pubmed] | [DOI] | | | 34 |
Design, synthesis, and characterization of novel substituted 1,2,4-oxadiazole and their biological broadcast |
|
| Paranjay H. Parikh, Jignesh B. Timaniya, Mrugesh J. Patel, Kaushal P. Patel | | Medicinal Chemistry Research. 2020; 29(3): 538 | | [Pubmed] | [DOI] | | | 35 |
Ethnobotanical study of selected medicinal plants traditionally used in the rural Greater Mpigi region of Uganda |
|
| Fabien Schultz, Godwin Anywar, Barbara Wack, Cassandra Leah Quave, Leif-Alexander Garbe | | Journal of Ethnopharmacology. 2020; 256: 112742 | | [Pubmed] | [DOI] | | | 36 |
Paradigm shift in efforts to end TB by 2025 |
|
| K.S. Sachdeva, Malik Parmar, Raghuram Rao, Sandeep Chauhan, Vaibhav Shah, Ra Pirabu, Deepak Balasubramaniam, Bhavin Vadera, S. Anand, Manu Mathew, Hardik Solanki, V.V. Sundar | | Indian Journal of Tuberculosis. 2020; 67(4): S48 | | [Pubmed] | [DOI] | | | 37 |
Isoniazid–phytochemical conjugation: A new approach for potent and less toxic anti-TB drug development |
|
| Shasank S. Swain, Sudhir K. Paidesetty, Rabindra N. Padhy, Tahziba Hussain | | Chemical Biology & Drug Design. 2020; 96(2): 714 | | [Pubmed] | [DOI] | | | 38 |
Synthesis, biological evaluation and molecular modelling insights of 2-arylquinazoline benzamide derivatives as anti-tubercular agents |
|
| Satyaveni Malasala, Md Naiyaz Ahmad, Jitendra Gour, Manjulika Shukla, Grace Kaul, Abdul Akhir, Srikanth Gatadi, Y.V. Madhavi, Sidharth Chopra, Srinivas Nanduri | | Journal of Molecular Structure. 2020; 1218: 128493 | | [Pubmed] | [DOI] | | | 39 |
Current status of point-of-care diagnostic devices in the Indian healthcare system with an update on COVID-19 pandemic |
|
| Aditya Narayan Konwar, Vivek Borse | | Sensors International. 2020; 1: 100015 | | [Pubmed] | [DOI] | | | 40 |
Copper mediated one-pot synthesis of quinazolinones and exploration of piperazine linked quinazoline derivatives as anti-mycobacterial agents |
|
| Satyaveni Malasala, Jitendra Gour, Md. Naiyaz Ahmad, Srikanth Gatadi, Manjulika Shukla, Grace Kaul, Arunava Dasgupta, Y. V. Madhavi, Sidharth Chopra, Srinivas Nanduri | | RSC Advances. 2020; 10(71): 43533 | | [Pubmed] | [DOI] | | | 41 |
Altered systemic levels of acute phase proteins in tuberculous lymphadenitis and modulation after treatment |
|
| Gokul Raj Kathamuthu, Kadar Moideen, Nathella Pavan Kumar, Rathinam Sridhar, Dhanaraj Baskaran, Subash Babu, Martin E. Rottenberg | | PLOS ONE. 2020; 15(5): e0233426 | | [Pubmed] | [DOI] | | | 42 |
Molecular detection of multidrug resistance pattern and associated gene mutations in M. tuberculosis isolates from newly diagnosed pulmonary tuberculosis patients in Addis Ababa, Ethiopia |
|
| Melaku Tilahun, Ezra Shimelis, Teklu Wogayehu, Gebeyehu Assefa, Getachew Wondimagegn, Alemayehu Mekonnen, Tsegaye Hailu, Kidist Bobosha, Abraham Aseffa, Hasnain Seyed Ehtesham | | PLOS ONE. 2020; 15(8): e0236054 | | [Pubmed] | [DOI] | | | 43 |
Tendência e caracterização epidemiológica da tuberculose em Alagoas, 2007-2016 |
|
| Clodis Maria Tavares, Amanda Maria Silva da Cunha, Nataly Mayara Cavalcante Gomes, Ana Beatriz de Almeida Lima, Igor Michel Ramos dos Santos, Mileyse da Silva Acácio, Daniella Marques dos Santos, Carlos Dornels Freire de Souza | | Cadernos Saúde Coletiva. 2020; 28(1): 107 | | [Pubmed] | [DOI] | | | 44 |
Factors Affecting Tuberculosis Patients’ Quality of Life in Surabaya, Indonesia |
|
| Ni Njoman Juliasih, Ni Made Mertaniasih, Cholichul Hadi, . Soedarsono, Reny Mareta Sari, Ilham Nur Alfian | | Journal of Multidisciplinary Healthcare. 2020; Volume 13: 1475 | | [Pubmed] | [DOI] | | | 45 |
The Biotin Biosynthetic Pathway in Mycobacterium tuberculosis is a Validated Target for the Development of Antibacterial Agents |
|
| Matthew R. Bockman, Neeraj Mishra, Courtney C. Aldrich | | Current Medicinal Chemistry. 2020; 27(25): 4194 | | [Pubmed] | [DOI] | | | 46 |
Piperonal: The Journey so Far |
|
| Jain Akash, Chaudhary Dushyant, Chaudhary Jasmine | | Mini-Reviews in Medicinal Chemistry. 2020; 20(18): 1846 | | [Pubmed] | [DOI] | | | 47 |
TO SEE THE IMPACT OF LOCKDOWN IN COVID19 PANDEMIC ON TUBERCULAR PATIENTS IN A TERTIARY CARE CENTRE OF HILLY AREA. |
|
| Subhash Chander, Ritin Sharma, Ankit Chaudhary, Rakesh Chauhan | | INDIAN JOURNAL OF APPLIED RESEARCH. 2020; : 33 | | [Pubmed] | [DOI] | | | 48 |
Microscopic Observation Drug Susceptibility (MODS) Assay: A Convenient Method for Determining Antibiogram of Clinical Isolates of Mycobacterium tuberculosis in Ghana |
|
| Enid Owusu, Mercy Jemima Newman | | Medical Sciences. 2020; 8(1): 5 | | [Pubmed] | [DOI] | | | 49 |
Squamous Cell Carcinoma in the Post Tuberculosis Lung after 30 Years of Treatment Completion |
|
| Arulprashanth Arulanantham, Umesh Jayarajah, Rohitha Dharmasiri, Rasarathinam Jeyanthakumar, Kamila Niroshan Siriwardena, Sujeewa Ilangamge | | Case Reports in Surgery. 2020; 2020: 1 | | [Pubmed] | [DOI] | | | 50 |
Contribution of community pharmacy in treating tuberculosis: A pharmacy centric study from Belagavi district |
|
| UdayKumar Rangaswamy, MadiwalayyaS Ganachari | | Journal of Reports in Pharmaceutical Sciences. 2020; 9(2): 246 | | [Pubmed] | [DOI] | | | 51 |
Bedaquiline: A Mini Review
|
|
| Nandhini Saravanabavan, Padmavathi Shanmuganathan, Manimekalai Kumarappan | | Annals of SBV. 2020; 8(1): 2 | | [Pubmed] | [DOI] | | | 52 |
Prevalence, diagnosis, management and control of important diseases of ruminants with special reference to indian scenario |
|
| Mani Saminathan, Rajneesh Rana, Muthannan Andavar Ramakrishnan, Kumaragurubaran Karthik, Yashpal Singh Malik, Kuldeep Dhama | | Journal of Experimental Biology and Agricultural Sciences. 2016; 4(3S): 338 | | [Pubmed] | [DOI] | | | 53 |
The Role of Biotin in Bacterial Physiology and Virulence: a Novel Antibiotic Target for
Mycobacterium tuberculosis
|
|
| Wanisa Salaemae, Grant W. Booker, Steven W. Polyak, Indira T. Kudva, Bryan H. Bellaire | | Microbiology Spectrum. 2016; 4(2) | | [Pubmed] | [DOI] | | | 54 |
Doctorsæ compliance with national guidelines and clinical pathway on the treatment of tuberculosis inpatients in Hubei, China |
|
| Xiaofei Zheng,Fangying Zhong,Xinping Zhang | | Journal of Evaluation in Clinical Practice. 2014; : n/a | | [Pubmed] | [DOI] | | | 55 |
Risk Factors of Tuberculosis Infection Among HIV/AIDS Patients in Burkina Faso |
|
| Ziemlé Clément Méda,Issiaka Sombié,Olivier W.C. Sanon,Daouda Maré,Donald E. Morisky,Yi-Ming Arthur Chen | | AIDS Research and Human Retroviruses. 2013; 29(7): 1045 | | [Pubmed] | [DOI] | | | 56 |
Burgeoning double burden of tuberculosis and diabetes in India: Magnitude of the problem – Strategies and solutions |
|
| Preety Sharma,Fehmida Visnegarwala,Vinay Tripathi | | Clinical Epidemiology and Global Health. 2013; | | [Pubmed] | [DOI] | | | 57 |
Pharmacovigilance and Public Health Ethics |
|
| Torbjörn Callréus | | Pharmaceutical Medicine. 2013; 27(3): 157 | | [Pubmed] | [DOI] | | | 58 |
Risk factors of tuberculosis infection among HIV/AIDS patients in Burkina Faso |
|
| Méda, Z.C. and Sombié, I. and Sanon, O.W.C. and Maré, D. and Morisky, D.E. and Chen, Y.-M.A. | | AIDS Research and Human Retroviruses. 2013; 29(7): 1045-1055 | | [Pubmed] | | | 59 |
Pharmacovigilance and public health ethics |
|
| Callréus, T. | | Pharmaceutical Medicine. 2013; 27(3): 157-164 | | [Pubmed] | | | 60 |
Effect of Piper nigrum on in-vitro release of isoniazid from oral microspheres |
|
| Pingale, P. and Ravindra, R.P. | | International Journal of Pharma and Bio Sciences. 2013; 4(1): 1027-1036 | | [Pubmed] | | | 61 |
Molecular Epidemiology of Mycobacteriosis in Wildlife and Pet Animals |
|
| Schrenzel, M.D. | | Veterinary Clinics of North America - Exotic Animal Practice. 2012; 15(1): 1-23 | | [Pubmed] | | | 62 |
Dermatomyositis and chest radiography leading to the diagnosis of lung cancer and subsequent confusions in staging due to the presence of tuberculosis |
|
| Revannasiddaiah, S. and Gupta, M.K. and Rastogi, M. and Kesari, A.A.R. and Seam, R.K. and Gupta, M. and Chauhan, S. and Madabhavi, I. | | BMJ Case Reports. 2012; | | [Pubmed] | | | 63 |
Molecular Epidemiology of Mycobacteriosis in Wildlife and Pet Animals |
|
| Mark D. Schrenzel | | Veterinary Clinics of North America: Exotic Animal Practice. 2012; 15(1): 1 | | [Pubmed] | [DOI] | | | 64 |
Gene dose effect of NAT2 variants on the pharmacokinetics of isoniazid and acetylisoniazid in healthy Chinese subjects |
|
| Chen, B. and Cao, X. and Li, J. | | Drug Metabolism and Drug Interactions. 2011; 26(3): 113-118 | | [Pubmed] | | | 65 |
Gene dose effect of NAT2 variants on the pharmacokinetics of isoniazid and acetylisoniazid in healthy Chinese subjects |
|
| Chen Bing,Cao Xiaomeia,Li Jinhenga | | Drug Metabolism and Drug Interactions. 2011; 26(3) | | [Pubmed] | [DOI] | |
|
|
|
|
|
|
|
|
|
|
|
|
| Article Access Statistics | | | Viewed | 17135 | | | Printed | 485 | | | Emailed | 11 | | | PDF Downloaded | 760 | | | Comments | [Add] | | | Cited by others | 65 | | |
|
|
